BioCentury
ARTICLE | Company News

Actavis, Debiopharm sales and marketing update

December 22, 2014 8:00 AM UTC

Actavis’ Actavis Specialty Pharmaceuticals Co. subsidiary and Debiopharm launched a six-month dosing option of 22.5 mg Trelstar triptorelin pamoate in Canada to treat hormone-dependent advanced prostate cancer. Actavis has U.S. and Canadian rights to the product from Debiopharm. Trelstar is a controlled-release formulation of triptorelin pamoate, a synthetic GnRH/LHRH receptor agonist (see BioCentury, Feb. 10). ...